Related Experiment Videos
Spinal myoclonus responsive to topiramate
Antonio Siniscalchi1, Franco Mancuso, Emilio Russo
1Department of Neuroscience, "Annunziata" Hospital, Cosenza, Italy.
Movement Disorders : Official Journal of the Movement Disorder Society
|September 25, 2004
Summary
Spinal segmental myoclonus is rare in peripheral nerve disorders. Topiramate (TPM) effectively reduced myoclonus in an amputation stump, offering new treatment possibilities.
Area of Science:
- Neurology
- Clinical Neuroscience
Background:
- Spinal segmental myoclonus is an uncommon neurological condition.
- Its occurrence in peripheral neurological disorders is rare.
- Limited data exists on pharmacological treatments, especially for myoclonus in amputation stumps.
Observation:
- A patient presented with segmental myoclonus localized to an amputation stump.
- The patient had a peripheral neurological disorder contributing to the myoclonus.
Findings:
- Topiramate (TPM) treatment resulted in significant amelioration of the spinal myoclonus.
- This case suggests potential efficacy of TPM for this specific type of myoclonus.
Implications:
- Topiramate may be a viable therapeutic option for spinal segmental myoclonus in amputation stumps.
- Further research is warranted to confirm TPM's efficacy in larger patient cohorts.
- This finding expands treatment considerations for rare movement disorders.